Aclaris Therapeutics Highlights AD and Asthma Data Catalysts at Oppenheimer Healthcare Conference [Yahoo! Finance]
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Ra Antibody ATI-052
Aclaris Therapeutics to Participate in Two February Healthcare Conferences [Yahoo! Finance]